Harshal Abhyankar

List of Publications by Year
in descending order

20 papers	1,099 citations	933447 10 h-index	1281871 11 g-index
20 all docs	20 docs citations	20 times ranked	1427 citing authors

#	Article	IF	Citations
1	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood, 2014, 124, 3007-3015.	1.4	352
2	<i>BRAF-V600E</i> expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine, 2014, 211, 669-683.	8.5	346
3	Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood, 2016, 128, 2533-2537.	1.4	122
4	Differentiating Skin-Limited and Multisystem Langerhans CellÂHistiocytosis. Journal of Pediatrics, 2014, 165, 990-996.	1.8	77
5	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCHâ€associated neurodegeneration and mass lesions. Cancer, 2018, 124, 2607-2620.	4.1	73
6	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	30.7	38
7	Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Advances, 2020, 4, 87-99.	5.2	25
8	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood, 2021, 137, 1777-1791.	1.4	25
9	Activating <i>MAPK1</i> (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget, 2017, 8, 46065-46070.	1.8	24
10	A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood, 2017, 130, 2229-2232.	1.4	15
11	Prevalence of the <i>BRAF</i> ^{V600E} mutation in Greek adults with Langerhans cell histiocytosis. Pediatric Hematology and Oncology, 2022, 39, 540-548.	0.8	2
12	A â€œnon-fratricidalâ€•Î±Î²- T Cell Receptor That Targets Survivin Expressed By Hematological Malignancies. Blood, 2013, 122, 141-141.	1.4	0
13	Plasma Biomarker Profiling In Langerhans Cell Histiocytosis: Risk-Stratifying The Inflammatory Storm. Blood, 2013, 122, 2854-2854.	1.4	0
14	Inflammatory Plasma Proteins Predict Disease Severity and Response to Therapy in Patients with LCH. Blood, 2015, 126, 4072-4072.	1.4	0
15	A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis. Blood, 2015, 126, 4059-4059.	1.4	0
16	Clonal, Exhausted and Activated Infiltrating T Lymphocytes in Langerhans Cell Histiocytosis Lesions. Blood, 2016, 128, 3708-3708.	1.4	0
17	Inherited Genetic Risk Factors and Langerhans Cell Histiocytosis Relapse Events. Blood, 2018, 132, 4278-4278.	1.4	0
18	Whole Exome Analysis Reveals Key Genomic Differences between Sporadic and Endemic Pediatric Burkitt Lymphoma. Blood, 2018, 132, 4117-4117.	1.4	0

#	Article	IF	Citations
19	Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH. Blood, 2019, 134, 3602-3602.	1.4	0
20	Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort. Blood, 2019, 134, 2773-2773.	1.4	0